Arwa O. Al Khatib

Amman, AM, Jordan

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 30 publications

Corrigendum to "Genomic landscape of Mycobacterium tuberculosis: Identifying mutation hotspots and stable regions for implications for drug development" [New Microb New Infect 68, (2025) 101674].

Corrigendum to "Genomic landscape of Mycobacterium tuberculosis: Identifying mutation hotspots and stable regions for implications for drug development" [New Microb New Infect 68, (2025) 101674].

Journal: New microbes and new infections
Published: June 12, 2026

Corrigendum to "Emergence of novel sublineages of Mycobacterium tuberculosis in Pakistan" [Int. J. Med. Microbiol. 321 (2025) 151684].

Corrigendum to "Emergence of novel sublineages of Mycobacterium tuberculosis in Pakistan" [Int. J. Med. Microbiol. 321 (2025) 151684].

Journal: International journal of medical microbiology : IJMM
Published: May 11, 2026

Novel seleno-ureido hybrids targeting head and neck cancer and beyond: design, synthesis, and apoptosis-mediated anticancer evaluation.

Novel seleno-ureido hybrids targeting head and neck cancer and beyond: design, synthesis, and apoptosis-mediated anticancer evaluation.

Journal: RSC advances
Published: April 26, 2026

Challenges in translating GINA asthma recommendations into practice: a qualitative study of healthcare professionals in Jordan.

Challenges in translating GINA asthma recommendations into practice: a qualitative study of healthcare professionals in Jordan.

Journal: BMJ open
Published: April 22, 2026

Co-Loaded PEGylated Nanoliposomes of Bendamustine and Rutin: Formulation, Release Kinetics, and a Hybrid Predictive Modeling Framework.

Co-Loaded PEGylated Nanoliposomes of Bendamustine and Rutin: Formulation, Release Kinetics, and a Hybrid Predictive Modeling Framework.

Journal: Pharmaceutics
Published: April 13, 2026

Covalent drugs reimagined: from cysteine-targeted inhibitors to proteome-informed precision therapeutics.

Covalent drugs reimagined: from cysteine-targeted inhibitors to proteome-informed precision therapeutics.

Journal: Bioorganic chemistry
Published: March 16, 2026

Discovery of Caralluma-derived pregnane glycosides as potent and selective cholinesterase inhibitors: integrated in silico and in vitro evaluation.

Discovery of Caralluma-derived pregnane glycosides as potent and selective cholinesterase inhibitors: integrated in silico and in vitro evaluation.

Journal: RSC advances
Published: February 21, 2026

Hybrid benzylidene thiazolidine-2,4-diones as potent apoptosis-inducing anticancer agents: design-driven optimization, cytotoxic profiling, and mechanistic validation in prostate cancer.

Hybrid benzylidene thiazolidine-2,4-diones as potent apoptosis-inducing anticancer agents: design-driven optimization, cytotoxic profiling, and mechanistic validation in prostate cancer.

Journal: RSC advances
Published: February 14, 2026

Fragment merging design, synthesis, and biological evaluation of novel methyl Selanyl- And thiazolidinedione-based hybrids as potent anticancer inducing apoptosis and cell cycle arrest.

Fragment merging design, synthesis, and biological evaluation of novel methyl Selanyl- And thiazolidinedione-based hybrids as potent anticancer inducing apoptosis and cell cycle arrest.

Journal: Bioorganic & medicinal chemistry
Published: January 21, 2026

Receptor-interacting protein kinase 2 (RIPK2): Structural insights, pathophysiological roles, and medicinal chemistry advances in inhibitor design.

Receptor-interacting protein kinase 2 (RIPK2): Structural insights, pathophysiological roles, and medicinal chemistry advances in inhibitor design.

Journal: Bioorganic chemistry
Published: December 28, 2025

Targeting cell cycle and apoptotic pathways with newly synthesized diselenide-linked imidazolone analogues with strong CDK6-targeting potential.

Targeting cell cycle and apoptotic pathways with newly synthesized diselenide-linked imidazolone analogues with strong CDK6-targeting potential.

Journal: RSC advances
Published: December 28, 2025

Organoselenium-based Schiff bases and amidic acid derivatives as promising anticancer agents targeting breast cancer by downregulating BCL-2: design, synthesis, and biological evaluation.

Organoselenium-based Schiff bases and amidic acid derivatives as promising anticancer agents targeting breast cancer by downregulating BCL-2: design, synthesis, and biological evaluation.

Journal: RSC advances
Published: November 29, 2025
Showing 1-12 of 30

Last Updated: 09/26/2026